1. Lilly: Alzheimer's disease drug Solanezumab
It is very difficult to find a cure for Alzheimer's disease. It takes a lot of money to develop a “killer†product, and Eli has put a lot of effort and cost into it. In November, Lilly's headquarters announced that its Alzheimer's disease drug Solanezumab failed in a phase III clinical trial, which is seen as a hope for treating Alzheimer's disease. This is the second failure of Solanezumab in the final clinical trial, the first failure occurred in 2012. This time, Eli Lilly chose to focus the indications for mild Alzheimer's disease and used the "delayed start" theory. However, clinical phase III data showed that the Solanezumab treatment group did not significantly slow cognitive decline in data performance compared with the placebo group. With the failure of Solanezumab, Lilly announced that it will lay off staff in the sales team in 2017 to solve Solanezumab's accounting problems.
2, Bristol-Myers Squibb: lung cancer drug Opdivo
Bristol-Myers Squibb (BMS) issued a statement in August that failed Opdivo as a monotherapy for previously untreated non-small cell lung cancer. PD1 immunosuppressant Opdivo This clinical trial was conducted in a wider patient population, with PDL1 levels as low as 5% in some patients. After the clinical failure of Opdivo, BMS announced that it will reorganize the R&D unit. In late October, the situation got worse. According to Cory Renauer, an expert at The Motley Fool, clinical trials have shown that the majority of patients receiving standard chemotherapy survive 40% longer than those who use Opdivo, and there are no signs of worsening the condition. The failure of the Opdivo clinical trial led to a 16% drop in BMS shares.
3, Bai Jian: multiple sclerosis medicine Opicinumab (lingo-1 antibody)
Baijian's Opicinumab is a clinically researched, fully human-derived monoclonal antibody that effectively repairs nerve damage caused by multiple sclerosis. The gradual dissection of myelin leads to nerve damage in patients with multiple sclerosis. Lingo-1 is an important target for Baijian research for more than ten years. It is a membrane protein that can inhibit myelination. In June, the failure of the Phaseinumab Phase II clinical trial caused Baijian's share price to plummet and lost up to $8 billion in market value in one day. The drug did not meet the secondary endpoint at the primary endpoint of the clinical trial.
Hotel Safe,Guest Room Safe,Mini Safe Box,Digital Safe Box
Hebei Yingbo Safe Boxes Co.,Ltd , https://www.ybsafebox.com